Sec Form 4 Filing - BioPlus Sponsor LLC @ BioPlus Acquisition Corp. - 2021-12-07

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person BioPlus Sponsor LLC 2. Issuer Name and Ticker or Trading Symbol BioPlus Acquisition Corp. [ BIOS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 533 AIRPORT BOULEVARD, SUITE 400 3. Date of Earliest Transaction (MM/DD/YY) 12/07/2021 (Street) BURLINGAME, CA94010 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A ordinary shares 12/07/2021 J( 1 ) 380,000 A $ 10 380,000 I See footnote( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Sponsor Loan $ 10 12/07/2021 J( 3 ) ( 3 ) ( 3 ) Class A ordinary shares 500,000 $ 5,000,000 $ 3,600,000 I See footnote( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other BioPlus Sponsor LLC 533 AIRPORT BOULEVARD SUITE 400 BURLINGAME, CA94010 X Explorer Parent LLC 533 AIRPORT BOULEVARD SUITE 400 BURLINGAME, CA94012 X Founder Holdings LLC 533 AIRPORT BOULEVARD SUITE 400 BURLINGAME, CA94012 X VIEUX ALEX SERGE C/O BIOPLUS ACQUISITION CORP. 260 MADISON AVENUE, SUITE 800 NEW YORK, NY10016 X Fletcher Steven C. C/O BIOPLUS ACQUISITION CORP. 260 MADISON AVENUE, SUITE 800 NEW YORK, NY10016 X Signatures /s/ Explorer Parent LLC, By: Founder Holdings LLC, its managing member, By: Steven Fletcher, a Managing Member, By: /s/ Alex Vieux, a Managing Member 12/07/2021 Signature of Reporting Person Date /s/ BioPlus Sponsor LLC, By: /s/ Steven Fletcher, a Managing Member 12/07/2021 Signature of Reporting Person Date /s/ Founder Holdings LLC; By: /s/ Steven Fletcher, a Managing Member, By: /s/ Alex Vieux, a Managing Member 12/07/2021 Signature of Reporting Person Date /s/ Steven Fletcher 12/07/2021 Signature of Reporting Person Date /s/ Alex Vieux 12/07/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Consists of 380,000 placement units purchased by BioPlus Sponsor LLC ("Sponsor") for $10.00 per unit in a private placement transaction with the Issuer. Each such unit consists of one Class A ordinary share andone-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable 30 days after the completion of the Issuer's business combination transaction. ( 2 )Sponsor is the record holder of the securities reported herein. Alex Vieux and Steven Fletcher are managing members of Sponsor and of Founder Holdings LLC, which is the managing member of Explorer Parent LLC, which is a member of Sponsor. By virtue of these relationships, each of these entities and individuals may be deemed to share beneficial ownership of the securities held of record by Sponsor. Each of them disclaims any such beneficial ownership except to the extent of their pecuniary interest therein. ( 3 )The Sponsor Loan is convertible at the option of Sponsor into Sponsor Loan Units at a conversion price of $10.00 per unit at any time upuntil the consummation of the Issuer's business combination transaction. Each Sponsor Loan Unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable 30 days after the completion of the Issuer's businesscombination transaction

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.